Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05491525 · ClinicalTrials.gov registry record · Phase 2
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
A Phase 2 study of Neurogenic Detrusor Overactivity, sponsored by Urovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 6
- Study locations
NCT05491525 is a Phase 2 study of Neurogenic Detrusor Overactivity that is actively recruiting participants, run by Urovant Sciences. The registered enrollment target is 85 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT05491525, a Phase 2 study of Neurogenic Detrusor Overactivity, is actively recruiting participants, sponsored by Urovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
Conditions Studied
Interventions
- DRUG Vibegron
Study Locations (6)
California
- Children's Hospital of Orange County - Orange
Florida
- Nemours Childrens Health, Jacksonville - Jacksonville
Kansas
- Wichita Urology Group - Wichita
Louisiana
- Childrens Hospital New Orleans - New Orleans
New York
- Albany Medical College - Albany
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05491525
The ClinicalTrials.gov registry entry for NCT05491525 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurogenic Detrusor Overactivity appearing as the primary indexed condition, and to 1 intervention - of which Vibegron is the first listed.
NCT05491525 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05491525 about?
NCT05491525 is a clinical study titled "A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC". The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
What is the current status of trial NCT05491525?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2022-10-12. Estimated completion is 2027-09.
What conditions does trial NCT05491525 study?
This clinical trial studies the following conditions: Neurogenic Detrusor Overactivity.
What interventions are being tested in trial NCT05491525?
The interventions under investigation include: Vibegron (DRUG).
Who is sponsoring clinical trial NCT05491525?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05491525 being conducted?
This trial has 6 study locations across California, Florida, Kansas, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Detrusor Overactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.